Search Results
Search results for "assay development"
Results found for "assay development"
- đź“° GPCR Weekly News, January 23 to 29, 2023
Methods & Updates in GPCR Research Development and Characterization of a Highly Selective Turn-On Fluorescent Global BioPharma Conference Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.
- đź“° GPCR Weekly News, March 25 to March 31, 2024
Hoare's workshop for individuals who live and work in developing countries. ligand binding affinity and modulation of 5-HT2B GPCR activity: implications for drug discovery and development VMAT2 Inhibitor, in Healthy Adults Confo Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development
- đź“° GPCR Weekly News, October 30 to November 4, 2023
Hannes Schihada and his lab team developed fluorescent analogues for real-time binding studies of orphan signalling molecule to exert direct functional effects in primary cultures of osteoblasts and osteoclasts Development NEW Post-Doctoral Associate NEW Team Leader Antibody Discovery Staff Scientist (AC-TAP) in Database Development
- Ermium Therapeutics has constituted its SAB
Advisory Board comprising international leaders in GPCRs pharmacology, immunology, drug discovery and development
- đź“° GPCR Weekly News, February 13 to 19, 2023
Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential. Computational drug design postdoc at the Department of Drug Design and Pharmacology Software / database development PhD student at Department of Drug Design and Pharmacology Software / database development postdoc at
- Trainees, this is for you...
Would you like to develop your presentation skills? Give a talk or present a poster at the Dr.
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
concept of biased agonism has been effectively leveraged in drug discovery, as demonstrated by the development By selectively targeting specific signaling pathways, it is possible to develop drugs with improved efficacy
- đź“° GPCR Weekly News, March 4 to 10, 2024
whole-genome SNP-based analysis Industry News Boehringer Ingelheim and Sosei Heptares join forces to develop Deciphering the role of GPCRs in obesity pathology for drug development GPCR Events, Meetings, and Webinars
- Discovery On Target, October 17-20, 2022, Boston, USA
emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development
- đź“° GPCR Weekly News, August 7 to 13, 2023
chemical biology: a mini-review YAP/TAZ: Molecular pathway and disease therapy Primary cilia in skeletal development Business Update for Second Quarter and First Half of 2023 Novo Nordisk to acquire Inversago Pharma to develop
- Crinetics Pharmaceuticals announced the formation of an independently operated new company...
Radionetics aims to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization Radionetics aims to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the
- ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships
Standard Time SAN FRANCISCO & SHANGHAI- ShouTi Inc., a clinical-stage global biopharmaceutical company developing
- đź“° GPCR Weekly News, February 20 to 26, 2023
Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential. Computational drug design postdoc at the Department of Drug Design and Pharmacology Software / database development PhD student at Department of Drug Design and Pharmacology Software / database development postdoc at
- Trevena Reports Second Quarter 2022 Results and Provides Business Update
(Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel
- Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...
CFTX-1554 For The Treatment Of Neuropathic Pain "— Confo’s first drug candidate moves into clinical development CFTX-1554 is being developed as a non-opioid approach to the treatment of neuropathic pain, a debilitating
- Effects of Small Molecule Ligands on ACKR3 Receptors
as stromal derived factor 1 and their G protein coupled receptors are well-known regulators of the development The development of more selective ACKR3 ligands should allow us to better appreciate the unique roles
- How a Failed Experiment Created a Powerful GPCR Imaging Tool
Collaboration, Chemistry, and the Pivot That Changed the Project Goal: Â Develop a photo-switchable GPCR
- A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets in...
The structure, function, and involvement of adhesion GPCRs in cancer development have been discussed
- Rhodopsin as a Molecular Target to Mitigate Retinitis Pigmentosa
people worldwide and being the most prevalent cause of visual handicap among working populations in developed molecule compounds that have been evaluated as rhodopsin modulators to be considered as leads for the development
- Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic ...
Therefore, a better understanding of the pathophysiology of hepatic fibrosis and the development of related GPCRs in hepatic stellate cells (HSCs), the primary cells that regulate liver fibrosis, may lead to the development of multiple GPCRs expressed in HSCs, their roles in liver fibrogenesis, and finally speculate on the development
- Function and structure of bradykinin receptor 2 for drug discovery
Although several B2R agonists and antagonists have been developed, icatibant is the only B2R antagonist
- đź“° GPCR Weekly News, April 15 to 21, 2024
Hoare's workshop for individuals who live and work in developing countries. We define a developing country based on World Bank Classifications for its 2024 fiscal year.
- đź“° GPCR Weekly News - January 2 to 8, 2023
Research Collaboration Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.
- Molecular insights into psychedelic drug action
Essential to the further development of such applications, however, is a clearer understanding of how
- A Chemical Biology Toolbox Targeting the Intracellular Binding Site of CCR9: Fluorescent Ligands ...
CCR9) antagonist and previous phase III clinical candidate for the treatment of Crohn's disease, we developed To chemically induce CCR9 degradation, we then developed the first PROTAC targeting the IABS of GPCRs
- Why GPCR Biologic Drugs Stabilize Active States Small Molecules Struggle to Reach
The lesson it comes from develops what follows: biased signaling at peptide receptors, antibody-driven
- Addex Therapeutics To Release Full-Year 2021 Financial Results And Host Conference Call On March 10
, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development
- Neurotransmitters: Potential Targets in Glioblastoma
ligands acting on neurotransmitter receptors have shown great potential for inhibiting GBM growth and development
- Emerging approaches for decoding neuropeptide transmission
These complex properties have driven the need for development of specialized tools that can sense neuropeptide
- đź“° GPCR Weekly News, September 25 to October 1, 2023
collaborates with Exscientia plc in deal worth up to $674M 2023 Half-Year Financial Results and Exciting Developments at Aelis Farma Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its




